New Combination for Asthma Shows Encouraging Results in Delivering Efficacy and Fast Onset of Action

CAMBRIDGE, England, September 19, 2010 – Data presented at the European Respiratory Society (ERS) congress
demonstrate that a new fixed-dose combination therapy of fluticasone
propionate (FP), an inhaled corticosteroid, and formoterol fumarate (FORM), a
long-acting beta2-agonist, is as effective in treating asthma as one of the
current market leaders in Europe, fluticasone propionate/salmeterol xinafoate
(FP/SAL), but has a more [...]